» Articles » PMID: 10772425

Effect of Aging on the Incidence of Digoxin Toxicity

Overview
Specialty Pharmacology
Date 2000 Apr 20
PMID 10772425
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the relationship of the therapeutic serum digoxin concentration (SDC) range (0.5-2 ng/mL, as recommended in previous clinical studies) with the incidence of digoxin toxicity during digoxin maintenance therapy.

Methods: Subjects included all inpatients (n = 462) and outpatients (n = 437) receiving digoxin oral maintenance therapy for heart failure and/or atrial fibrillation with tachycardia at Kosei Hospital, Anjo, Japan. SDC and blood chemistry analysis were determined, and a 24-hour Holter electrocardiographic recording was performed when the SDC was at the presumed steady-state concentration.

Results: Analysis of clinical data showed that there was an overlapping (toxic and nontoxic) range of SDCs in which the incidence of digoxin toxicity was patient-dependent (1.4-2.9 ng/mL). No patient exhibited signs or symptoms of digoxin toxicity when the SDC was <1.4 ng/mL; all patients had evidence of toxicity when the SDC was >3 ng/mL. Additionally, it was shown that the concentration range of this overlapping range tended to broaden and shift to lower concentrations with increasing age. Patients with signs of toxicity when their SDCs were in the overlapping range had normal serum creatinine, blood urea nitrogen, digoxin clearance, creatinine clearance, and potassium concentrations, except for a significantly higher mean age than patients without toxicity. The incidence of digoxin toxicity was dependent on increasing age in patients whose SDCs were within the recommended therapeutic range. Moreover, clinical evidence of digoxin toxicity in patients >71 years old was 26.5%, despite their SDCs falling between 1.4 and 2 ng/mL.

Conclusions: Increased age is most likely associated with enhanced susceptibility to digoxin toxicity, possibly due to unknown pharmacodynamic changes. This raises the possibility that patients >71 years show clinical evidence of digoxin toxicity despite having SDCs within the recommended therapeutic range.

Citing Articles

Population pharmacokinetic analysis and dosage recommendations for digoxin in Japanese patients with atrial fibrillation and heart failure using real-world data.

Hirai T, Kasai H, Naganuma M, Hagiwara N, Shiga T BMC Pharmacol Toxicol. 2022; 23(1):14.

PMID: 35144695 PMC: 8830040. DOI: 10.1186/s40360-022-00552-y.


Cardiac glycosides display selective efficacy for STK11 mutant lung cancer.

Kim N, Yim H, He N, Lee C, Kim J, Choi J Sci Rep. 2016; 6:29721.

PMID: 27431571 PMC: 4949473. DOI: 10.1038/srep29721.


Retrospective evaluation of patients with elevated digoxin levels at an emergency department.

Limon G, Ersoy G, Oray N, Bayram B, Limon O Turk J Emerg Med. 2016; 16(1):17-21.

PMID: 27239633 PMC: 4882205. DOI: 10.1016/j.tjem.2015.10.001.


Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010.

See I, Shehab N, Kegler S, Raja Laskar S, Budnitz D Circ Heart Fail. 2013; 7(1):28-34.

PMID: 24300242 PMC: 4697444. DOI: 10.1161/CIRCHEARTFAILURE.113.000784.


A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers.

Teng R, Butler K Eur J Clin Pharmacol. 2013; 69(10):1801-8.

PMID: 23748750 DOI: 10.1007/s00228-013-1543-3.